139 related articles for article (PubMed ID: 26992948)
1. Mutations of TP53 gene in adult acute lymphoblastic leukemia at diagnosis do not affect the achievement of hematologic response but correlate with early relapse and very poor survival.
Salmoiraghi S; Montalvo ML; Ubiali G; Tosi M; Peruta B; Zanghi P; Oldani E; Boschini C; Kohlmann A; Bungaro S; Intermesoli T; Terruzzi E; Angelucci E; Cavattoni I; Ciceri F; Bassan R; Rambaldi A; Spinelli O
Haematologica; 2016 Jun; 101(6):e245-8. PubMed ID: 26992948
[No Abstract] [Full Text] [Related]
2. Mutations and deletions of the TP53 gene predict nonresponse to treatment and poor outcome in first relapse of childhood acute lymphoblastic leukemia.
Hof J; Krentz S; van Schewick C; Körner G; Shalapour S; Rhein P; Karawajew L; Ludwig WD; Seeger K; Henze G; von Stackelberg A; Hagemeier C; Eckert C; Kirschner-Schwabe R
J Clin Oncol; 2011 Aug; 29(23):3185-93. PubMed ID: 21747090
[TBL] [Abstract][Full Text] [Related]
3. TP53 alterations in relapsed childhood acute lymphoblastic leukemia.
Yu CH; Chang WT; Jou ST; Lin TK; Chang YH; Lin CY; Lin KH; Lu MY; Chen SH; Wu KH; Wang SC; Chang HH; Su YN; Hung CC; Lin DT; Chen HY; Yang YL
Cancer Sci; 2020 Jan; 111(1):229-238. PubMed ID: 31729120
[TBL] [Abstract][Full Text] [Related]
4. TP53 mutations are frequent in adult acute lymphoblastic leukemia cases negative for recurrent fusion genes and correlate with poor response to induction therapy.
Chiaretti S; Brugnoletti F; Tavolaro S; Bonina S; Paoloni F; Marinelli M; Patten N; Bonifacio M; Kropp MG; Sica S; Guarini A; Foà R
Haematologica; 2013 May; 98(5):e59-61. PubMed ID: 23403321
[No Abstract] [Full Text] [Related]
5. TP53 in adult acute lymphoblastic leukemia.
Salmoiraghi S; Rambaldi A; Spinelli O
Leuk Lymphoma; 2018 Apr; 59(4):778-789. PubMed ID: 28679301
[TBL] [Abstract][Full Text] [Related]
6. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.
Mühlbacher V; Zenger M; Schnittger S; Weissmann S; Kunze F; Kohlmann A; Bellos F; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 Jun; 53(6):524-36. PubMed ID: 24619868
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of p53 mutations in newly diagnosed Burkitt's lymphoma and acute lymphoblastic leukemia: a report of 48 cases.
Preudhomme C; Dervite I; Wattel E; Vanrumbeke M; Flactif M; Lai JL; Hecquet B; Coppin MC; Nelken B; Gosselin B
J Clin Oncol; 1995 Apr; 13(4):812-20. PubMed ID: 7707106
[TBL] [Abstract][Full Text] [Related]
8. TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis.
Stengel A; Schnittger S; Weissmann S; Kuznia S; Kern W; Kohlmann A; Haferlach T; Haferlach C
Blood; 2014 Jul; 124(2):251-8. PubMed ID: 24829203
[TBL] [Abstract][Full Text] [Related]
9. MYC Expression Is Associated With p53 Expression and TP53 Aberration and Predicts Poor Overall Survival in Acute Lymphoblastic Leukemia/Lymphoma.
Gao L; Harbaugh B; Parr K; Patel P; Golem S; Zhang D; Woodroof J; Cui W
Am J Clin Pathol; 2022 Jan; 157(1):119-129. PubMed ID: 34528662
[TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of TP53 gene in Tunisian familial hematological malignancies and sporadic acute leukemia cases.
Hamadou WS; Besbes S; Bourdon V; Youssef YB; Laatiri MA; Noguchi T; Khélif A; Sobol H; Soua Z
Fam Cancer; 2017 Jan; 16(1):153-157. PubMed ID: 27619989
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia.
Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; Kronnie GT; Wiesmüller L; Stilgenbauer S; Selivanova G; Debatin KM; Meyer LH
Haematologica; 2020 Jan; 105(1):170-181. PubMed ID: 31073076
[TBL] [Abstract][Full Text] [Related]
12. Frequent and simultaneous epigenetic inactivation of TP53 pathway genes in acute lymphoblastic leukemia.
Vilas-Zornoza A; Agirre X; Martín-Palanco V; Martín-Subero JI; San José-Eneriz E; Garate L; Álvarez S; Miranda E; Rodríguez-Otero P; Rifón J; Torres A; Calasanz MJ; Cruz Cigudosa J; Román-Gómez J; Prósper F
PLoS One; 2011 Feb; 6(2):e17012. PubMed ID: 21386967
[TBL] [Abstract][Full Text] [Related]
13. Therapy-induced mutations drive the genomic landscape of relapsed acute lymphoblastic leukemia.
Li B; Brady SW; Ma X; Shen S; Zhang Y; Li Y; Szlachta K; Dong L; Liu Y; Yang F; Wang N; Flasch DA; Myers MA; Mulder HL; Ding L; Liu Y; Tian L; Hagiwara K; Xu K; Zhou X; Sioson E; Wang T; Yang L; Zhao J; Zhang H; Shao Y; Sun H; Sun L; Cai J; Sun HY; Lin TN; Du L; Li H; Rusch M; Edmonson MN; Easton J; Zhu X; Zhang J; Cheng C; Raphael BJ; Tang J; Downing JR; Alexandrov LB; Zhou BS; Pui CH; Yang JJ; Zhang J
Blood; 2020 Jan; 135(1):41-55. PubMed ID: 31697823
[TBL] [Abstract][Full Text] [Related]
14.
Comeaux EQ; Mullighan CG
Cold Spring Harb Perspect Med; 2017 Mar; 7(3):. PubMed ID: 28003275
[TBL] [Abstract][Full Text] [Related]
15. Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With IKZF3 Deletion and TP53 Mutation: Comparison With Pediatric Patients.
Fang M; Becker PS; Linenberger M; Eaton KD; Appelbaum FR; Dreyer Z; Airewele G; Redell M; Lopez-Terrada D; Patel A; Rabin KR; Lu X
Am J Clin Pathol; 2015 Aug; 144(2):263-70. PubMed ID: 26185311
[TBL] [Abstract][Full Text] [Related]
16. Impact of
Firtina S; Erbilgin Y; Hatirnaz Ng O; Karaman S; Karakas Z; Celkan TT; Gelen SA; Yildirmak Y; Ozbek U; Sayitoglu M
Scand J Clin Lab Invest; 2023 May; 83(3):187-193. PubMed ID: 37029683
[TBL] [Abstract][Full Text] [Related]
17. Tumor suppressor gene alteration in adult acute lymphoblastic leukemia (ALL). Analysis of retinoblastoma (Rb) and p53 gene expression in lymphoblasts of patients with de novo, relapsed, or refractory ALL treated in Southwest Oncology Group studies.
Tsai T; Davalath S; Rankin C; Radich JP; Head D; Appelbaum FR; Boldt DH
Leukemia; 1996 Dec; 10(12):1901-10. PubMed ID: 8946929
[TBL] [Abstract][Full Text] [Related]
18. Somatic TP53 mutations are preleukemic events in acute lymphoblastic leukemia.
Chitadze G; Stengel A; John-Klaua C; Bruckmüller J; Trautmann H; Kotrova M; Darzentas F; Kelm M; Pal K; Darzentas N; Bastian L; Kehden B; Wessels W; Ströh AS; Oberg HH; Altrock PM; Baer C; Meggendorfer M; Gökbuget N; Baldus CD; Haferlach C; Brüggemann M
Blood; 2023 Mar; 141(13):1640-1644. PubMed ID: 36450137
[No Abstract] [Full Text] [Related]
19. Evaluating approaches to enhance survival in children with hypodiploid acute lymphoblastic leukaemia (ALL).
Miller L; Kobayashi S; Pauly M; Lew G; Saxe D; Keller F; Qayed M; Castellino S
Br J Haematol; 2019 May; 185(3):613-616. PubMed ID: 30255927
[No Abstract] [Full Text] [Related]
20. Does TP53 guard ALL genomes?
Moorman AV
Blood; 2014 Jul; 124(2):160-1. PubMed ID: 25013160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
